7 completed, 5 terminated, 3 recruiting, 1 active not recruiting. 16 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 16 | Completed 7, Terminated 5, Recruiting 3, Active not recruiting 1 |
| Phase 2 | 4 | Terminated 4 |
Follow ALL: new trials by email Literature Review of ALL trials Research Report on ALL
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy Infusion of CD34 selected hematopoietic stem cells - AML, ALL | Phase 1 | Recruiting | University of Alabama at Birmingham | 50 | 2025-04-22 | 2026-04-13 |
| Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies Tagraxofusp, Fludarabine, Cytarabine - Hematologic Malignancy, AML | Phase 1 | Recruiting | Therapeutic Advances in Childhood Leukemia Consortium | 54 | 2022-11-11 | 2024-12-06 |
| Venetoclax Plus Inotuzumab for B-ALL Venetoclax, Dexamethasone, Inotuzumab Ozogamicin - B-cell Acute Lymphoblastic Leukemia, B-Cell Lymphoma | Phase 1 | Active not recruiting | Dana-Farber Cancer Institute | 23 | 2021-09-24 | 2026-01-29 |
| GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL Cohort 1, GNR-084, Cohort 2, GNR-084, Cohort 3, GNR-084 - B-precursor Acute Lymphoblastic Leukemia, ALL | Phase 1 / Phase 2 | Terminated | AO GENERIUM | 14 | 2020-10-15 | 2026-09-21 |
| Haplo Peripheral Blood Sct In GVHD Prevention FLUDARABINE, CYCLOPHOSPHAMIDE, TBI - GVHD, AML | Phase 1 | Completed | Zachariah Michael DeFilipp | 25 | 2020-08-14 | 2025-07-20 |
| Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia Ruxolitinib, Cyclophosphamide, Cytarabine - Acute Lymphoblastic Leukemia, ALL, Childhood | Phase 1 | Recruiting | University of Chicago | 15 | 2019-05-28 | 2026-06-29 |
| Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders T-allo10 - AML - Acute Myeloid Leukemia, MDS (Myelodysplastic Syndrome) | Phase 1 | Terminated | Roncarolo, Maria Grazia, MD | 5 | 2017-08-30 | 2024-07-18 |
| Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia OTS167IV - AML, Advanced MDS | Phase 1 / Phase 2 | Terminated | OncoTherapy Science, Inc. | 32 | 2016-04-01 | 2021-11-24 |
| Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies CD22-CAR - NHL, Large Cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 134 | 2014-12-12 | 2026-04-28 |
| Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma Anti-Cluster of Differentiation (CD)19-Chimeric antigen receptor (CAR) - ALL, B Cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 53 | 2012-06-29 | 2020-08-31 |
| POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients Plerixafor Dose Escalation - Relapsed/Refractory AML, Relapsed/Refractory ALL | Phase 1 | Completed | Seattle Children's Hospital | 20 | 2011-03-01 | 2018-09-07 |
| Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies TG02 citrate, Carfilzomib, Dexamethasone - AML, ALL | Phase 1 | Completed | Tragara Pharmaceuticals, Inc. | 120 | 2010-08-01 | 2016-05-06 |
| A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia STA-9090 (ganetespib) - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 1 | Completed | Synta Pharmaceuticals Corp. | 29 | 2009-08-01 | 2014-09-18 |
| Umbilical Cord Blood Transplant for Hematological Malignancies Ex Vivo CD3/CD28 costimulated Umbilical Cord Blood T cells, Observation Arm - CML, AML | Phase 1 | Completed | University of Pennsylvania | 5 | 2009-01-01 | 2016-08-19 |
| Myeloablative Allogeneic Stem Cell Transplantation Using a Naive T-Cell Depleted Peripheral Blood Stem Cell Graft Naive T-cell Depleted Stem Cell Transplant, Stem Cell Transplant No Manipulation, Isolex device from Baxter - ALL, ANLL | Phase 1 / Phase 2 | Terminated | Duke University | 15 | 2007-07-01 | 2013-11-25 |
| Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies Rapamycin, High dose etoposide and cytarabine (HiVAC) - ALL, Burkitt's Lymphoma | Phase 1 / Phase 2 | Terminated | Abramson Cancer Center at Penn Medicine | 4 | 2007-01-01 | 2025-11-05 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma (7) · Leukemia, Myeloid, Acute (5) · Hodgkin Disease (4) · Burkitt Lymphoma (3) · Leukemia (3) · Leukemia, Biphenotypic, Acute (3) · Lymphoma, B-Cell (3) · Lymphoma, Non-Hodgkin (3) · Blast Crisis (2) · Dendritic Cell Sarcoma, Interdigitating (2) · Hematologic Neoplasms (2) · Multiple Myeloma (2) · Myelodysplastic Syndromes (2) · Anemia, Refractory, with Excess of Blasts (1) · Blastic Plasmacytoid Dendritic Cell Neoplasm (1)
Hemic and Lymphatic Diseases (15) · Neoplasms (14) · Hematologic Diseases (13) · Neoplasms by Histologic Type (13) · Immune System Diseases (12) · Immunoproliferative Disorders (12) · Lymphoproliferative Disorders (12) · Lymphatic Diseases (11) · Leukemia (9) · Leukemia, Lymphoid (8) · Lymphoma (7) · Leukemia, Myeloid (6) · Bone Marrow Diseases (5) · Pathological Conditions, Signs and Symptoms (5) · Disease Attributes (4)
Dexamethasone (4) · Calcium Dobesilate (3) · Cytarabine (3) · Cyclophosphamide (2) · Methotrexate (2) · Sirolimus (2) · Vincristine (2) · fludarabine (2) · Administration, Intravenous (1) · Azacitidine (1) · Doxorubicin (1) · Etoposide (1) · Hydrocortisone (1) · Inotuzumab Ozogamicin (1) · Melphalan (1)
National Cancer Institute (NCI) (2) · AO GENERIUM (1) · Abramson Cancer Center at Penn Medicine (1) · Dana-Farber Cancer Institute (1) · Duke University (1) · OncoTherapy Science, Inc. (1) · Roncarolo, Maria Grazia, MD (1) · Seattle Children's Hospital (1) · Synta Pharmaceuticals Corp. (1) · Therapeutic Advances in Childhood Leukemia Consortium (1) · Tragara Pharmaceuticals, Inc. (1) · University of Alabama at Birmingham (1) · University of Chicago (1) · University of Pennsylvania (1) · Zachariah Michael DeFilipp (1)
United States (14) · Australia (1) · Canada (1) · Russia (1)
Nirali N Shah, M.D. (2) · Adam Lamble, MD (1) · David Porter, MD (1) · Elizabeth Hexner, MD (1) · Marlise R Luskin, MD, MSCE (1) · Mitchell Horwitz, MD (1) · Oksana A. Markova, MD (1) · Olatoyosi Odenike, MBBS (1) · Rajni Agarwal, MD (1) · Selina Luger, MD (1) · T Parrott (1) · Todd Cooper, DO (1) · Wendy Stock, MD (1) · Zachariah DeFilipp, MD (1)
PMID 34687939, PMID 37486616, PMID 25319501, PMID 26858124, PMID 32286905, PMID 32883871, PMID 33764809, PMID 34309174, PMID 35148417, PMID 35622074, PMID 37295816, PMID 38376944, PMID 41411486, PMID 42789493
P01CA049605 (1)